Befloxatone synthelabo

IDrugs

Volumn 2, Issue 3, 1999, Pages 247-253

  Emilien, Gerard ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEFLOXATONE; BROFAROMINE; IPRONIAZID; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; PHENELZINE; TOLOXATONE; TRANYLCYPROMINE;

CLINICAL TRIAL; COGNITION; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG UPTAKE; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PANIC; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PSYCHOMOTOR ACTIVITY; SHORT SURVEY; SOCIAL PHOBIA;

EID: 0033004234     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (63)

1. 161071 Befoxatone, a new reversible MAO-A Inhibitor: Interaction studies with dietary tyramine in the rat Fankhauser C, Charieras T, Caille D CANJPHYSIOL PHARMACOL1994 72 Suppl 1 P 13.21.16 Befloxatone is a selective and potent MAO-inHbHor, comparable to moclobemide and brofaromine. There were, however, no recognizable advantages in its use at this stage.
2. 161072 Befloxatone, a new reversible competitive MAO-A inhibitor Curet O, Damoiseau G, Aubin N, Sontag N, Sauvage C CAN J PHYSIOL PHARMACOL1994 72 Suppl 1 P13.21.24 Befloxatone is a selective, competitive and reversible MAO-inhibitor whkh is approximately 10-fold more potent than moclobemide, although their profiles are otherwise very similar.
3. 166816 Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?. Dosiert P J NEURAL TRANSM SUPPL 1994 41 269-279
4. 169197 Effects of befloxatone on psychomotor performance and memory Patat A, Warot D, Berlin I, Durrieu G. Zeleniuk I, Puech A PROC BR PHARMACOL SOC1994 13-16 Dec P309 A single oral dose of befloxatone from 5 to 20 mg was free of any detrimental effects on skilled performance, vigilance and memory and did not disrupt sleep. This study suggests that single doses of befloxatone do not have any sedative or amnestic effects which are likely to interfere with activities of everyday life.
5. 169198 Oral tyramine presser effect after chronic treatment with befloxatone In healthy volunteers Durrieu G, Patat A, Berlin I. Armand P, Mdinier P, Caille Ph, Rosenzweig P PROC BR PHARMACOL SOC 1994 13-16 Dec P321 A standardized meal contains less than 40 mg of tyramine in total. These results indicate a satisfactory safety margin of befloxatone and suggest that during clinical trials befloxatone may be administered at the end of a meal in dosage of up to 20 mg once daily without dietary restrictions.
6. 170287 Biochemical Pharmacology of befloxatone (MD370503), a new potent reversible MAO-A inhibitor Rovei V, Caille D, Curet O, Ego D, Jarreau FX J NEURAL TRANSM SUPPL 1994 41 339-347
7. 174426 Use of free DHPG plasma levels to assess equipotency of 2 dosage regimens of befloxatone, a reversible MAO-A inhibitor Patat A, Le Coz F, Gandon JM, Beck A, Durrieu G, Curet O, Allain H CLIN PHARMACOL THER1995 57 2 PI-46 This study suggests that once-daily dosage with befloxatone should be feasible.
8. 176452 Synthelabo highlights R&D pipeline SCRIP 1995 2019 19 177914 Synthelabo ANNUAL REPORT 1994 184880 Effects of befloxatone on psychomotor performance and memory Palat A, Warot D, Berlin I. Durrieu G, Zeleniuk I, Puech A BR J CUN PHARMACOL 1995 39 565P-566P
9. 190257 Effects of befloxatone on psychomotor performances and cognitive functions in elderly subjects. Fatal A, Gandon JM, Coz F Le, Durrieu G, Cimarosti I, Allain H, Flosenweig P EUR NEUROPSYCHOPHARMACOL 1995 5 3 Abs P-2-123
10. 192637 Syrrthelabo in-licenses two compounds SCRIP 1995 2076 11
11. 193176 Presser effect of oral tyramine during treatment with befloxatone a new reversible monoamine oxidase-A inhibitor, in healthy subjects Patat A, Berlin I, Durrieu G, armand P, Rtoussi S, MoSnier P. Caille P J CUN PHARMACOL1995 35 6 633
12. 197335 Antidepressives of the 3rd, 4th and 5th generation. Svestka J CESKPSYCHIATRI99490 1 3-19
13. 201435 Synthelabo reports positive results PHARM BUSINESS NEWS 199511 24 Oct
14. 204578 Regulation of 5-hydroxvtryptamine release from rat midbrain raphe nuclei by 5-hydroxytryptamine1 D receptors: effect of tetrodotoxin, G protein inactivation and long-term antidepressant administration Pineyro G, Blier P J PHARMACOL EXP THER 1996 276 2 697-707
15. 212069 Pharmacodynamics and pharmacokinetics of two dose regimens of Befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers Patat A, Coz F le, Dubruc C. Gandon J M, Durrieu G, Cimarosti I, Jezequel S, Curet O, Zieleniuk I, Allain H, Rosenzweig P J CUN PHARMACOL 1996 36 3 216-229 Pharmacokinetics and pharmacodynamics of befloxatone in normal volunteers.
16. 213230 Synthelabo ANNUAL REPORT 1995 213693 Functional characterization of 5-HT,0 autoreceptors on the modulation of 5-HT release in guinea-pig mesencephalic raphe, hippocampus and frontal cortex. El Mansari M, Blier P BR J PHARMACOL 1996118 3 681 -689
17. 218227 Synthelabo Meeting for Financial Analysts October 1995 Synthelabo ANNUAL REPORT 1995 October
18. 219410 Synthelabo Meeting for financial analysts April 1995 Synthelabo COMPANY BROCHURE 1995 April 12
19. 220537 MAO-A inhibitors - State of the art Gleiter CH, Volz H P EXP OPIN INVEST DRUGS 1996 5 4 409-419
20. 220538 Food and drug interactions with monoamine oxidase inhibitors. How safe are the newer agents? Berlin I, Lecrubier Y CNS DRUGS 1996 5 6 40313
21. 220539 Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. II. Pharmacological profile. Caille D, Bergis OE, Fankhauser C, Gardes A, Adam R, Charieras T, Grosset A, Rovei V, Jarreau FX J PHARMACOL EXP THER1996 2771 265-277 A good concise report which describes the in vivo behavioral actions of befloxatone in rat in various models.
22. 220541 Befloxatone, a new reversible and selective monoamine oxidase-A inhibitor. I. Biochemical profile. Curet O, Damoiseau G, Aubin N, Sorrtag N, Rovei V, Jarreau FX J PHARMACOL EXP THER 19962771253-264 In vitro and in vivo mechanistic studies wüh befloxatone.
23. 220542 Biochemical profile of befloxatone, a selective and reversible MAO-A inhibitor. Curet O, Damoiseau G, Aubin N, Sauvage C, Sontag N, Carter C, Benavides J, Scatton B SOC NEUROSCIABSTR1995 21 1 -31733
24. 220543 The placebo effect in healthy volunteers: Influence of experimental conditions on physiological parameters during phase I studies. Rosenzweig P, Brohier S, Zpfel A BR J CUN PHARMACOL 1995 39 6 657-664
25. 220544 Presser effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects. Patat A, Berlin I, Durrieu G, Armand P, Fitoussi S, Molinier P, Caille P J CUN PHARMACOL1995 35 6 633-643 Presser actions of beloxatone in conjunction with tyramine in normal volunteers.
26. 220545 Oral tyramine pressor effect after chronic treatment with befloxatone in healthy volunteers. Durrieu G, Patat A, Berlin I, Armand P, Molinier P, Caille P, Rosenzweig P BP J CUN PHARMACOL 1995 39 5 574P
27. 220549 Lack of interaction between befloxatone and ethanol on psychomotor performance in healthy subjects. Patat A, Ramaekers J, MunCewerff N, Durrieu G, O'Hanlon J CUN PHARMACOL THER 1995572207
28. 220550 Use of free DHPG plasma levels to assess equipotency of 2 dosage regimens of befloxatone, a reversible MAO-A Inhibitor. Patat A, Le Coz F, Gandon JM, Beck A, Durrieu G, Curet O, Allan H CUN PHARMACOL THER 1995 57 2 146
29. 220551 Effects of single and multiple doses of a new reversible MAO-A inhibitor, befloxatone, on psychomotor performance and memory in healty subjects. Patat A, Gandon JM, Durrieu G, Le Coz F, Curet O, Cimarosti I, Allain H HUM PSYCHOPHARMACOL 1995 10 2111-125 Demonstration of a lack of sedative or amnestic actions in normal volunteers.
30. 220553 Safety and MAO-A inhibition of befloxatone in elderly subjects. Patat A, Gandon JM, Le Coz F, Durrieu G, Cimarosti I, Allain H, Caroff J, Rosenzweig P THERAPIE 1995 50 Suppl 104
31. 220554 Effects on psychomotor and cognitive functions of multiple doses of befloxatone. Allain H, Patat A, Gandon JM, Le Coz F, Raoul P, Durrieu G EUR J CUN INVEST 1995 25 Suppl. 2 A63
32. 220555 Brofaromine: Insight into the nature of drug development Volz H P, Gleiter CH, Struck M, Moller H J CNS DRUGS 1995 3 1 1 -8
33. 220556 Modulation of 5-HT release in the guinea-pig brain following long-term administration of antidepressant drugs. Blier P, Bouchard C BR J PHARMACOL 1994113 2 485495
34. 220558 Effects of befloxatone, a new potent reversible MAO-A inhibitor, on cortex and striatum monoamines in freely moving rats. Curet O, Damoiseau G, Labaune JP, Rove! V, Jarreau FX J NEURAL TRANSM SUPPL 1994 41 5
35. 220559 Experimental and theoretical study of reversible monoamine oxidase inhibitors: structural approach of the active site of the enzyme. Wouters J, Mouraau F, Vercauteren DP, Evrard G, Durant F, Koenig JJ, Ducrey F, Jarreau FX J NEURAL TRANSM SUP. 1994 41
36. 220560 Befloxatone, a reversible MAO-A inhibitor, suppresses paradoxical sleep in the rat Depoortere H, Francon D J SLEEP RES 1994 3 Suppl. 162
37. 220561 Electrophysiologic evidence for desensrtization of alpha 2adrenoceptors on serotonin terminals following long-term treatment with drugs increasing noreplnephrine synaptic concentration. Mongeau R, de Montigny C, Blier P NEUROPSYCHOPHARMACOLOGYiaM 101 41-51
38. 220562 Neurophysiological profile of befloxatone, a reversible MAO-A inhibitor. Caille D, Adam R, Lourdelet J, Avenet P, Despoortere H J SLEEP RES 1994 3 Suppl. 1 36
39. 220563 Effect of befloxatone, a new potent reversible MAO-A inhibitor, on extracellular and tissular serotonin and norepinephrine in rat frontal cortex. Damoiseau G, Aubin N, Curet O, Rovei V, Jarreau F X FUNDAM CUN PHARMACOL 1993 7 7 354
40. 228719 Antagonism by way 100635, A 5-HT(1A) antagonist, of the effects of fluoxetine and befloxatone in the forced swin test
41. Moser PC, Sanger DJ SOC NEUROSCIABSTR1996 22 1 180 231990 Idee eyes success IN VIV0199614 23-32
42. 238183 Pharmacotherapeutic considerations for psychiatric disorders: Depression. Risby E, Donnigan D, Nemeroff CB HOSP FORMUL 1997 32 1 46-50+56-59
43. 242963 Synthelabo in hunt for European partner SCRIP 1997 222412
44. 256381 Synthelabo Meeting for Financial Analysts ANALYST REPORT 1997 April 9
45. 265545 Effects of befloxatone, a reversible selective 'monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects. Warot D, Berlin I, Patat A, Durrieu G, Zieleniuk I. Puech AJ J CLIN PHARMACOL 1996 36 10 942-950
46. 282893 Behavioural profiles of the reversible monoamineoxidase-A inhibitors befloxatone and moclobemide in an experimental model for screening anxiolytic and anti-panic drugs. Griebe! G, Perrault G, Sanger DJ PSYCHO-PHARMACOLOGY 1997 131 2 180-186
47. 283951 Safety and pharmacodynamic study of befloxatone after fluoxetine withdrawal Pinquier JL, Caplain H, Durrieu G, Zieleniuk I, Rosenweig P ANNU MEET AM SOC CLIN PHARMACOL 1998 99 New Orleans PII-60
48. 291369 Annual report - Synthelabo -1997 Synthelabo ANNUAL REPORT 1997
49. 296669 Monoamine oxidase A and B inhibitors. Jegham S, George P EXP OPIN THER RAT 1998 8 9 1143-1150
50. 299680 Use of chiral glycerol 2,3-carbonate in the synthesis of 3-aryl-2- oxazolidinones. Jegham S, Nedelec A, Bumier P, Guminski Y, Puech F, Koenig JJ, George P TETRAHEDRON LETT 199839254453-4454
51. 299681 Safety and pharmacodynamic study of befloxatone (B) after fluoxetine (F) withdrawal. Pinquier JL, Caplain H, Durrieu G, Zieleniuk l, Rosenzweig P CLIN PHARMACOL THER 1998 63 2 187 A small study in volunteers which indicates that a direct switch from fluoxetine to befloxatone may be easily performed without any safety concerns. After the switch, no clinically relevant changes were observed.
52. 299682 Effect of the reversible monoamine oxidase-A inhibitor befloxatone on the rat 5-hydroxytryptamine neurotransmission.
53. Haddjeri N, De Montigny C, Curet O, Blier P EUR J PHARMACOL 19983432-3179-192 Interesting paper which provides a good electrophysiological model in rats with relevant mechanistic aspects of drug action.
54. 299683 Structural aspects of monoamine oxidase and its reversible inhibition. Woulers J CURR MED CHEM1998 5 2 137-162
55. 299684 Antidepressant treatments enhance the tonic activation of the rat dorsal hippocampus 5-HT,A receptors. Haddjeri N, Blier P, De MONTIGNYC SOC NEUROSCIABSTR1997 23 1-2 969
56. 299685 EEC, MAO-A inhibition, pharmacokinetics and safety of befloxatone in the elderly. Patat A, Dubruc C, Deschamp C, Dum'eu G, Trocherie S, Cimarosti I, Allain H, Rosenzweig P, Gandon J. M HUM PSYCHOPHARMACOL 199712 6 557-571
57. 299686 Effects of befloxatone on EEC and cognitive functions in elderly subjects. Patat A, Trocherie S, Durrieu G, Cimarosti I, Allain H, Gandon JM, Rosenzweig P BR J CLIN PHARMACOL1997 43 5 552P
58. 299687 A study of the pharmacodynamic interaction between befloxatone and ethanol on performance and mood in healthy volunteers. Ramaekers JG, Muntjewerff ND, Uiterwijk MMC, Van Veggel LMA, Patat A, Durrieu G, O'Hanlon JF J PSYCHOPHARMACOL 199610 4 288-294
59. 299688 Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects. Luthringer R, Dago KT, Patat A, Caille P, Curet O, Durieu G, Rinaudo G, Toussaint M, Granier LA, Mâcher JP NEUROPSYCHOBIOLOGY1996 34 2 98-105 An excellent paper which provides a good study of befloxatone on EEG, CNV and P300, showing the non-sedative aspects of this product.
60. 305968 In vivo characterization of carbon-11 labelled befloxatone for PET study of monoamine oxydase-A (MAO-A)
61. Bottlaender M, Roumenov D, Guenther I, Dolle F, Bramoulle Y, Fuseau C, Curet O, Pinquier J-L, Jegham S. Crouzel C, Grognet JM, Maziere B SOC NEUROSCI ABSTR 1998 24 Part 2 729.5
62. 307879 Biochemical profile of SL-65.0477, a new mixed and reversible MAO-A/B inhibitor Curet O, Sontag N, Aubin N, Marc C, Jegham S. George P. Scatton B SOC NEUROSCI ABSTR 1998 24 Part 2 583.11 A company spokesperson confirmed1 that SL-65.0477 was 'not well tolerated' and that Synthelabo was investigating other compounds in the series.
63. 308390 Quantitative autoradiography of ('H)befloxatone binding. Curet O, Sauvage C SOC NEUROSCI ABSTR 1993 23rd 1-3933 A snort but interesting abstract that provides the order of binding site densities of fH] befloxatone.